Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Remuzzi

Showing results (701-710 of 895) with videos related to

Pageof 90
Sort By:
Blood Advances|December 1, 2021
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19Sistiana Aiello, Sara Gastoldi, Miriam Galbusera, et al.
Transplantation|February 24, 2007
DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic propertiesSistiana Aiello, Paola Cassis, Linda Cassis, et al.
Transplantation|November 9, 2007
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injuryPiero Ruggenenti, Norberto Perico, Eliana Gotti, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 14, 2008
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndromeJeffrey M Saland, Benjamin L Shneider, Jonathan S Bromberg, et al.
Frontiers in Immunology|July 7, 2025
C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patientsValeria Guaschino, Donata Santarsiero, Sara Gastoldi, et al.
Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.
BMJ Open|September 26, 2019
Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE)Marvin Gonzalez-Quiroz, Dorothea Nitsch, Sophie Hamilton, et al.
European Journal of Dermatology : EJD|November 15, 2006
Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter studyGianpaolo Tessari, Luigi Naldi, Luigino Boschiero, et al.
Frontiers in Medicine|March 8, 2021
Bergamo and Covid-19: How the Dark Can Turn to LightNorberto Perico, Stefano Fagiuoli, Fabiano Di Marco, et al.
Blood Purification|March 27, 2004
Nitric oxide synthetic capacity in relation to dialysate temperatureCharles H Beerenhout, Marina Noris, Jeroen P Kooman, et al.
Pageof 90

Showing results (701-710 of 895) with videos related to

Sort By:
Pageof 90
Blood Advances|December 1, 2021
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19Sistiana Aiello, Sara Gastoldi, Miriam Galbusera, et al.
Transplantation|February 24, 2007
DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25- cells with tolerogenic propertiesSistiana Aiello, Paola Cassis, Linda Cassis, et al.
Transplantation|November 9, 2007
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injuryPiero Ruggenenti, Norberto Perico, Eliana Gotti, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 14, 2008
Successful split liver-kidney transplant for factor H associated hemolytic uremic syndromeJeffrey M Saland, Benjamin L Shneider, Jonathan S Bromberg, et al.
Frontiers in Immunology|July 7, 2025
C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patientsValeria Guaschino, Donata Santarsiero, Sara Gastoldi, et al.
Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.
BMJ Open|September 26, 2019
Rationale and population-based prospective cohort protocol for the disadvantaged populations at risk of decline in eGFR (CO-DEGREE)Marvin Gonzalez-Quiroz, Dorothea Nitsch, Sophie Hamilton, et al.
European Journal of Dermatology : EJD|November 15, 2006
Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter studyGianpaolo Tessari, Luigi Naldi, Luigino Boschiero, et al.
Frontiers in Medicine|March 8, 2021
Bergamo and Covid-19: How the Dark Can Turn to LightNorberto Perico, Stefano Fagiuoli, Fabiano Di Marco, et al.
Blood Purification|March 27, 2004
Nitric oxide synthetic capacity in relation to dialysate temperatureCharles H Beerenhout, Marina Noris, Jeroen P Kooman, et al.
Pageof 90